Addressing Financial and Insurance Barriers to CAR T-Cell Therapy in Multiple Myeloma

This segment discusses how financial hurdles and insurance authorization delays can slow or derail access to CAR T-cell therapy for patients with multiple myeloma. Dr. Kaur explains that insurance approval for apheresis and manufacturing can take two to four weeks, creating significant lost time for patients with aggressive disease. Early introduction of support systems is critical. Dedicated financial counselors, social workers, and nurse navigators can guide patients through insurance requirements, coordinate documentation, and communicate with payors to reduce delays. Some manufacturers offer programs that cover the cost of apheresis before insurance authorization, helping initiate the process sooner. Housing assistance, caregiver support programs, and grants from nonprofit organizations can offset expenses related to required proximity to treatment centers. Ensuring these resources are engaged at the time of initial consult helps patients understand expectations, reduces anxiety about financial burden, and improves the likelihood that they will complete the referral pathway and receive CAR T-cell therapy.